Overview
Comprehensive hereditary and somatic BRCA testing supporting cancer risk assessment and PARP inhibitor therapy.
Why this Test Matters
Precision oncology depends on identifying clinically actionable genomic alterations. This assay helps clinicians select targeted therapies, evaluate immunotherapy eligibility, identify prognostic biomarkers, detect resistance mechanisms, and match patients to suitable clinical trials while minimizing sequential testing.
Who Should Consider this Test?
● Breast
● Ovarian
● Pancreatic
● Prostate cancer
● Strong family history
Applicable Cancer Types
Breast, Ovarian, Pancreatic, Prostate
What is Covered?
- Complete BRCA1/2
- SNVs
- InDels
- Large deletions
- Duplications
Clinical Utility
- Treatment selection
- Prognostic and predictive biomarkers
- Clinical trial matching
- Identification of actionable alterations
- Comprehensive clinical interpretation
Technology
High-depth sequencing with CNV analysiskey Features
| Parameter | Details |
|---|---|
|
Sample Type |
Blood or FFPE |
|
Samples |
1 FFPE block or 10–15 slides |
|
Turnaround Time |
~14 working days |
|
Report Includes |
Variant interpretation, therapy associations, clinically actionable biomarkers |
|
Quality |
High-depth NGS with rigorous QC |